Scholarlink

Objectives <p>Recent advances in therapeutics have substantially improved breast cancer treatment outcomes. However, data on prognostic factors after surgical resection of pulmonary metastases from breast cancer remain limited.</p> Methods <p>This single-center retrospective study analyzed data from patients with breast cancer who had undergone pulmonary metastasectomy between 2000 and 2023. We reviewed clinical and pathological parameters, including the disease-free interval (DFI), size and number of pulmonary metastases.</p> Results <p>This study included 33 patients. The median postoperative survival of breast cancer patients with lung metastasis was 40 (range 4–217) months. According to univariate analysis, hormone receptor-positive breast cancer, pStage I or II breast cancer, lung metastases &lt; 20&#xa0;mm, hormone receptor-positive lung metastases, absence of other metastases, and DFI ≥ 24 months were significantly associated with better survival. Multivariate analysis identified DFI &lt; 24 months (hazard ratio [HR] 9.520, 95% confidence interval [CI] 2.158–27.070) and&#xa0;tumor size ≥ 20&#xa0;mm (HR 4.958, 95% CI 1.290–27.550) independently predicted poorer survival; ≥ 2 metastatic lesions&#xa0;showed a&#xa0;non-significant trend&#xa0;toward worse outcomes (HR 3.272, 95% CI 0.913–11.090).</p> Conclusions <p>This study clarified the criteria for pulmonary metastasectomy in patients with breast cancer. Considering subtype changes between the primary tumor and metastases could enable personalized therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of prognostic factors after pulmonary resection for metastatic breast cancer: a 23-year single-institution retrospective study

  • 期刊论文

  • 发表日期：

    2025年10月16日

查看全文
  • Ryusei Yoshino,
  • Kengo Takahashi,
  • Nozomi Hatanaka,
  • Akane Ito,
  • Nanami Ujiie,
  • Shunsuke Yasuda,
  • Masahiro Kitada

摘要

Objectives

Recent advances in therapeutics have substantially improved breast cancer treatment outcomes. However, data on prognostic factors after surgical resection of pulmonary metastases from breast cancer remain limited.

Methods

This single-center retrospective study analyzed data from patients with breast cancer who had undergone pulmonary metastasectomy between 2000 and 2023. We reviewed clinical and pathological parameters, including the disease-free interval (DFI), size and number of pulmonary metastases.

Results

This study included 33 patients. The median postoperative survival of breast cancer patients with lung metastasis was 40 (range 4–217) months. According to univariate analysis, hormone receptor-positive breast cancer, pStage I or II breast cancer, lung metastases < 20 mm, hormone receptor-positive lung metastases, absence of other metastases, and DFI ≥ 24 months were significantly associated with better survival. Multivariate analysis identified DFI < 24 months (hazard ratio [HR] 9.520, 95% confidence interval [CI] 2.158–27.070) and tumor size ≥ 20 mm (HR 4.958, 95% CI 1.290–27.550) independently predicted poorer survival; ≥ 2 metastatic lesions showed a non-significant trend toward worse outcomes (HR 3.272, 95% CI 0.913–11.090).

Conclusions

This study clarified the criteria for pulmonary metastasectomy in patients with breast cancer. Considering subtype changes between the primary tumor and metastases could enable personalized therapies.